Latest & greatest articles for copd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd

1. COPD and COVID-19 for Healthcare Professionals

. There is no evidence to use or not to use oral or inhaled corticosteroids outside usual guidelines in COPD patients with COVID19. Antibiotics should be issued only if suspicion of secondary bacterial infection.” Please refer to that document. Please also refer to the NICE Rapid Guideline for the community-based care of patients with chronic obstructive pulmonary disease (COPD): https://www.nice.org.uk/guidance/ng168 This reiterates the importance of smoking cessation. Strongly encourage patients with COPD who (...) ), there is no routine indication to take rescue antibiotics or additional oral steroids. Do not offer patients with COPD a short course of oral corticosteroids and/or antibiotics to keep at home unless clinically indicated, as set out in the NICE guideline on chronic obstructive pulmonary disease in over 16s. There should be NO alteration to advanced rescue-pack prescribing or stockpiling inhalers. These seriously compromise the medicines supply chain and equitable access. Best practice at all times

2020 British Thoracic Society

2. Supervised pulmonary tele-rehabilitation versus pulmonary rehabilitation in severe COPD: a randomised multicentre trial Full Text available with Trip Pro

Permalink Copy Page navigation Thorax Actions . 2020 May;75(5):413-421. doi: 10.1136/thoraxjnl-2019-214246. Epub 2020 Mar 30. Supervised Pulmonary Tele-Rehabilitation Versus Pulmonary Rehabilitation in Severe COPD: A Randomised Multicentre Trial , , , , , , , , , , Affiliations Expand Affiliations 1 Respiratory Research Unit, Department of Respiratory Medicine, Hvidovre Hospital, Hvidovre, Denmark henrik.hansen.09@regionh.dk. 2 Department of Physical and Occupational Therapy, Bispebjerg Hospital (...) and Infectious Diseases, Hillerød Hospital, Hillerød, Denmark. 9 Department of Public Health, University of Copenhagen Faculty of Health Sciences, Copenhagen, Denmark. PMID: 32229541 DOI: Item in Clipboard Supervised Pulmonary Tele-Rehabilitation Versus Pulmonary Rehabilitation in Severe COPD: A Randomised Multicentre Trial Henrik Hansen et al. Thorax . 2020 May . Show details Thorax Actions . 2020 May;75(5):413-421. doi: 10.1136/thoraxjnl-2019-214246. Epub 2020 Mar 30. Authors

2020 EvidenceUpdates

3. Do Antibiotics Improve Patient Outcomes in Acute Exacerbations of Chronic Obstructive Pulmonary Disease? Full Text available with Trip Pro

, and severity of COPD exacerbations. Thorax . 2002 ; 57 : 759–764 | | | , x 7 Seemungal, T., Harper-Owen, R., Bhowmik, A. et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med . 2001 ; 164 : 1618–1623 | | | , x 8 Sethi, S. Bacteria in exacerbations of chronic obstructive pulmonary disease: phenomenon or epiphenomenon?. Proc Am Thorac Soc . 2004 ; 1 : 109–114 | | | , x 9 Bafadhel, M., McKenna, S (...) ., Frei, A., Steurer-Stey, C.A. et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev . 2018 ; 10 : CD010257 Limitations of this meta-analysis include no consideration of underlying chronic obstructive pulmonary disease severity across trials because of poor reporting of lung function and other parameters. Studies were not limited to patients with suspected bacterial infection, who demonstrate the greatest benefit from antibiotics. Thus, the lack

2020 Annals of Emergency Medicine Systematic Review Snapshots

4. myCOPD for self-management of chronic obstructive pulmonary disease

to the clinical effectiveness of the technology. Further information about how the evidence for this briefing was selected is available on request by contacting mibs@nice.org.uk. Published evidence Published evidence Three studies are summarised in this briefing, including 2 randomised controlled trials and 1 observational study. In total, there were 167 people with chronic obstructive pulmonary disease (COPD) in these studies. The clinical evidence and its strengths and limitations is summarised (...) myCOPD for self-management of chronic obstructive pulmonary disease myCOPD for self-management of chronic obstructive pulmonary disease Medtech innovation briefing Published: 1 April 2020 www.nice.org.uk/guidance/mib214 pathways Summary Summary • The technology technology described in this briefing is myCOPD. It helps people with chronic obstructive pulmonary disease (COPD) to manage their symptoms and reduce the number of healthcare visits they need. It also helps the healthcare professionals

2020 National Institute for Health and Clinical Excellence - Advice

5. Chronic obstructive pulmonary disease (COPD)

, is a major public health problem that is both preventable and treatable. COPD is characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and lungs to noxious articles or gases. Exacerbations and comorbidities contribute to overall severity in individual patients. Recommendations for the diagnosis and treatment of patients with concurrent COPD and asthma are excluded from this guideline because these patients (...) . In addition to identifying the recently published guidelines that meet the above standards, a literature search was conducted to identify studies relevant to the key questions that are not addressed by the external guidelines. External guidelines eligible for adapting ? 2019 Update of 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global strategy for the diagnosis, management and prevention of COPD ? 2018 KP National Clinical Practice Guideline: Chronic Obstructive Pulmonary Disease

2020 Kaiser Permanente Clinical Guidelines

6. Addressing therapeutic questions to help Canadian physicians optimize COPD management for their patients during the Covid-19 pandemic

. Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. Eur Respir J. 2020:2000547. 8. Lippi G, Henry BM. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). Respiratory Medicine. 2020. DOI: https://doi.org/10.1016/j.rmed.2020.105941 9. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223 (...) distancing in the workplace setting is difficult to implement. Until we fully understand the risks associated with SARS-CoV-2 infection in patients with chronic lung disease we have placed a high value on limiting exposure based on prior experience with influenza. COPD Management – General Statement In the absence of direct or indirect data that use of current inhaled COPD therapies impacts the severity of SARS-CoV-2 infection, we recommend that maintenance and exacerbation management for COPD

2020 Canadian Thoracic Society

7. Purified human alpha1-proteinase inhibitor (A1-PI) for the treatment of alpha1-proteinase inhibitor deficiency, leading to chronic obstructive pulmonary disease (COPD)

Purified human alpha1-proteinase inhibitor (A1-PI) for the treatment of alpha1-proteinase inhibitor deficiency, leading to chronic obstructive pulmonary disease (COPD) 1 Public Summary Document Application No. 1530 – Purified human alpha1-proteinase inhibitor for the treatment of alpha1-proteinase inhibitor deficiency, leading to chronic obstructive pulmonary disease Applicant: National Blood Authority (NBA) Date of MSAC consideration: MSAC 74th Meeting, 22-23 November 2018 Context for decision (...) : MSAC makes its advice in accordance with its Terms of Reference, visit the MSAC website 1. Purpose of application An application requesting National Product List (NPL) blood product listing of purified human alpha1-proteinase inhibitor (A1-PI) for the treatment of A1-PI deficiency, leading to chronic obstructive pulmonary disease (COPD), was received from the National Blood Authority (NBA) by the Department of Health. 2. MSAC’s advice to the Minister After considering the strength of available

2020 Medical Services Advisory Committee

8. Safety and Adverse Events after Targeted Lung Denervation for Symptomatic Moderate to Severe Chronic Obstructive Pulmonary Disease (AIRFLOW). A Multicenter Randomized Controlled Clinical Trial Full Text available with Trip Pro

: Targeted lung denervation (TLD) is a bronchoscopic radiofrequency ablation therapy for chronic obstructive pulmonary disease (COPD), which durably disrupts parasympathetic pulmonary nerves to decrease airway resistance and mucus hypersecretion. Objectives: To determine the safety and impact of TLD on respiratory adverse events. Methods: We conducted a multicenter, randomized, sham bronchoscopy-controlled, double-blind trial in patients with symptomatic (modified Medical Research Council dyspnea scale (...) treated with TLD combined with optimal pharmacotherapy had fewer study-defined respiratory adverse events, including hospitalizations for COPD exacerbation.Clinical trial registered with www.clinicaltrials.gov ( ). Keywords: anticholinergic; bronchoscopy; chronic obstructive pulmonary disease; nerves; targeted lung denervation. Figures Figure 1. 5 Respiratory adverse events between 3... Figure 1. 13 Respiratory adverse events between 3 and 6.5 months after bronchoscopy for the... Figure 1. Respiratory

2020 EvidenceUpdates

9. COVID-19 rapid guideline: community-based care of patients with chronic obstructive pulmonary disease (COPD)

COVID-19. Signpost to charities (such as the British Lung Foundation) and support groups (such as NHS Volunteer Responders), and UK government guidance on the mental health and wellbeing aspects of COVID-19. 1.2 Explain to patients with chronic obstructive pulmonary disease (COPD), and their families and carers, that they are at increased risk of severe illness from COVID-19. 1.3 Be aware that the NICE guideline on chronic obstructive pulmonary disease in over 16s defines severe airflow obstruction (...) , and they should take appropriate precautions such as: • performing airway clearance techniques in a well-ventilated room • performing airway clearance techniques away from other family members if possible • advising other family members not to enter the room until enough time has passed for aerosols to clear. Find out more from UK government guidance on COVID-19: infection prevention and control. COVID-19 rapid guideline: community-based care of patients with chronic obstructive pulmonary disease (COPD

2020 National Institute for Health and Clinical Excellence - Clinical Guidelines

10. Improving Lung Function in Severe Heterogenous Emphysema with the Spiration Valve System (EMPROVE). A Multicenter, Open-Label Randomized Controlled Clinical Trial Full Text available with Trip Pro

, and Blood Institute. COPD national action plan. Washington, D.C.: U.S. Department of Health and Human Services; 2017 [accessed 2018 Jul 6]. Available from: . van Agteren JE, Hnin K, Grosser D, Carson KV, Smith BJ. Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017;2:CD012158. - - Kaplan RM, Ries AL. Health-related quality of life in emphysema. Proc Am Thorac Soc. 2008;5:561–566. - - Vogelmeier CF, Criner GJ, Martínez FJ, Anzueto (...) similar articles Cited by 1 PubMed Central articles NS Hopkinson. Am J Respir Crit Care Med 200 (11), 1329-1331. 2019. PMID 31560561. References Wheaton AG, Cunningham TJ, Ford ES, Croft JB Centers for Disease Control and Prevention (CDC) Employment and activity limitations among adults with chronic obstructive pulmonary disease: United States, 2013. MMWR Morb Mortal Wkly Rep. 2015;64:289–295. - - U.S. Department of Health and Human Services, National Institutes of Health and National Heart, Lung

2019 EvidenceUpdates

11. Efficacy and safety of inhaled alpha1-antitrypsin in patients with severe alpha1-antitrypsin deficiency and frequent exacerbations of COPD (Abstract)

Efficacy and safety of inhaled alpha1-antitrypsin in patients with severe alpha1-antitrypsin deficiency and frequent exacerbations of COPD Patients with inherited α1-antitrypsin (AAT) deficiency (ZZ-AATD) and severe chronic obstructive pulmonary disease (COPD) frequently experience exacerbations. We postulated that inhalation of nebulised AAT would be an effective treatment.We randomly assigned 168 patients to receive twice-daily inhalations of 80 mg AAT solution or placebo for 50 weeks (...) in the AAT-treated group and 2.67 in the placebo group (p=0.31). More patients receiving AAT reported treatment-related treatment-emergent adverse events compared to placebo (57.5% versus 46.9%, respectively) and they were more likely to withdraw from the study. After the first year of the study, when modifications to the handling of the nebuliser were introduced, the rate of safety events in the AAT-treated group dropped to that of the placebo group.We conclude that in AATD patients with severe COPD

2019 EvidenceUpdates

12. European Respiratory Society guidelines on long-term home non-invasive ventilation for management of COPD Full Text available with Trip Pro

European Respiratory Society guidelines on long-term home non-invasive ventilation for management of COPD While the role of acute non-invasive ventilation (NIV) has been shown to improve outcome in acute life-threatening hypercapnic respiratory failure in COPD, the evidence of clinical efficacy of long-term home NIV (LTH-NIV) for management of COPD is less. This document provides evidence-based recommendations for the clinical application of LTH-NIV in chronic hypercapnic COPD patients.The (...) for improving the health outcome of COPD patients with chronic respiratory failure. The task force conditionally supports the application of LTH-NIV to improve health outcome by targeting a reduction in carbon dioxide in COPD patients with persistent hypercapnic respiratory failure. These recommendations should be applied in clinical practice by practitioners that routinely care for chronic hypercapnic COPD patients.Copyright ©ERS 2019.

2019 EvidenceUpdates

13. Comparative safety of biologic versus conventional synthetic DMARDs in rheumatoid arthritis with COPD: a real-world population study (Abstract)

Comparative safety of biologic versus conventional synthetic DMARDs in rheumatoid arthritis with COPD: a real-world population study Abatacept, a biologic DMARD, was associated with respiratory adverse events in a small subgroup of RA patients with chronic obstructive pulmonary disease (COPD) in a trial. Whether this potential risk is specific to abatacept or extends to all biologics and targeted synthetic DMARDs (tsDMARDs) is unclear. We assessed the risk of adverse respiratory events (...) associated with biologic and tsDMARDs compared with conventional synthetic DMARDs (csDMARDs) among RA patients with concomitant COPD in a large, real-world cohort.We used a prevalent new-user design to study RA patients with COPD in the US-based MarketScan databases. New users of biologic DMARDs and/or tsDMARDs were matched on time-conditional propensity scores to new users of csDMARDs. Adverse respiratory events were estimated using Cox models comparing current use of biologic/tsDMARDs with csDMARDs.The

2019 EvidenceUpdates

14. CTS guideline on pharmacotherapy in patients with COPD— 2019 update of evidence

of Canada, Richmond Hill, Ontario, Canada; j Institut Universitaire de Cardiologie et de Pneumologie de Qu ebec, Universit e Laval, Qu ebec, Quebec, Canada; k Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; l Respiratory Research Centre, University of Saskatchewan, Saskatoon, Saskatchewan, Canada ABSTRACT In this guideline update, we highlight important and new findings related to pharmacological therapy of chronic obstructive pulmonary disease (COPD (...) corticost eroïde en inhalation (CSI)/BALA, sauf chez les patients ayant d ej a subi des exac- erbations et dont le nombre d’ eosinophiles de sang p eriph erique est elev e. Il n’y a pas lieu de recourir a la monoth erapie de CSI; lorsqu’ils sont indiqu es, les CSI doivent ^ etre utilis es uniquement KEYWORDS Chronic obstructive pulmonary disease; COPD; guideline; pharmacotherapy; Canadian Thoracic Society; CTS CONTACT Jean Bourbeau jean.bourbeau@mcgill.ca Respiratory Epidemiology and Clinical Research

2019 Canadian Thoracic Society

15. Effect of a Hospital-Initiated Program Combining Transitional Care and Long-term Self-management Support on Outcomes of Patients Hospitalized With Chronic Obstructive Pulmonary Disease: A Randomized Clinical Trial. Full Text available with Trip Pro

Effect of a Hospital-Initiated Program Combining Transitional Care and Long-term Self-management Support on Outcomes of Patients Hospitalized With Chronic Obstructive Pulmonary Disease: A Randomized Clinical Trial. Patients hospitalized for chronic obstructive pulmonary disease (COPD) exacerbations have high rehospitalization rates and reduced quality of life.To evaluate whether a hospital-initiated program that combined transition and long-term self-management support for patients hospitalized (...) quality of life measured by the St George's Respiratory Questionnaire (SGRQ) at 6 months after discharge (score, 0 [best] to 100 [worst]; 4-point difference is clinically meaningful).Among 240 patients who were randomized (mean [SD] age, 64.9 [9.8] years; 61.7% women), 203 (85%) completed the study. The mean (SD) baseline SGRQ score was 62.3 (18.8) in the intervention group and 63.6 (17.4) in the usual care group. The mean number of COPD-related acute care events per participant at 6 months was 1.40

2019 JAMA

16. Pharmacologic and Nonpharmacologic Therapies in Adult Patients With Exacerbation of COPD

of Bias Appendix F. Results From Included Studies Appendix G. Results by Severity Appendix H. Adverse Events Appendix I. Inclusion and Exclusion Criteria of Included Studies Appendix J. Sensitivity Analysis Appendix K. Appendix References ES-1 Evidence Summary Background and Objectives Chronic obstructive pulmonary disease (COPD) is a common respiratory disease characterized by airflow limitation and chronic respiratory symptoms. The global prevalence is estimated to be greater than 10 percent (...) : MeiLan K. Han, M.D., M.S. University of Michigan Ann Arbor, MI Clare Hawkins, M.D. Aspire Health Care Houston, TX Cara Pasquale, M.P.H. COPD Patient Powered Research Network Washington, DC Antonello Punturieri, M.D., Ph.D. National Heart, Lung, and Blood Institute for Chronic Obstructive Pulmonary Disease (COPD)/Environment Bethesda, MD Mark Steffen, M.D., M.P.H. Blue Cross and Blue Shield of Minnesota Eagan, MN James J. Stevermer, M.D., M.S.P.H. Department of Family and Community Medicine University

2019 Effective Health Care Program (AHRQ)

17. Current and future direct healthcare cost burden of chronic obstructive pulmonary disease in Alberta, Canada

Current and future direct healthcare cost burden of chronic obstructive pulmonary disease in Alberta, Canada Current and future direct healthcare cost burden of chronic obstructive pulmonary disease in Alberta, Canada: Canadian Journal of Respiratory, Critical Care, and Sleep Medicine: Vol 0, No 0 | Search in: Journal Revue canadienne des soins respiratoires et critiques et de la médecine du sommeil 25 Views 0 CrossRef citations to date Altmetric Original Research Current and future direct (...) healthcare cost burden of chronic obstructive pulmonary disease in Alberta, Canada , , , & Published online: 02 Jul 2019 Abstract OBJECTIVES: To examine the resource use and healthcare costs for chronic obstructive pulmonary disease (COPD) in Alberta, Canada between 2008 and 2016 and model the future costs to 2030. METHODS: Interlinked hospitalization, ambulatory care, practitioner claims and drug databases in Alberta were used to identify COPD healthcare encounters and medications. Canadian Institution

2019 Institute of Health Economics

18. Procedure for lung volume reduction in severe lung emphysema

in the medium term (over 5 years ) due to reduced all-cause mortality as well as proof of harm due to a short- term (up to 1 year postoperatively) increase in all-cause mortality. In terms of other outcomes, there were hints of benefit regarding dyspnea (as the only reported symptom of chronic obstructive pulmonary disease [COPD]) and exacerbations as well as indications of benefit regarding improved exercise capacity and health-related quality of life. When compared to pulmonary rehabilitation (...) ? Dawid Pieper, Institute for Research in Operative Medicine, University Witten/Herdecke, Cologne, Germany ? Erich Stoelben, Lung Hospital Cologne-Merheim, Hospitals of Cologne City, Germany IQWiG thanks the external experts for their collaboration in the project. IQWiG employees ? Ulrike Paschen ? Christoph Mosch ? Stefan Sauerland ? Sibylle Sturtz ? Siw Waffenschmidt Keywords: Pneumonectomy, Bronchoscopy, Pulmonary Emphysema, Benefit Assessment Extract of final report N14-04 Version 1.0 LVR

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

19. Targeted lung denervation using catheter ablation for chronic obstructive pulmonary disease – Addendum to Commission H16-01

the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. H18-02 Targeted lung denervation using catheter ablation for chronic obstructive pulmonary disease – Addendum to Commission H16-01 1 Extract of addendum H18-02 Version 1.0 Targeted lung denervation for COPD 27 April 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Targeted lung (...) for COPD 27 April 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - ii - IQWiG employees involved in the addendum: ? Martina Lietz ? Julia Kreis ? Fabian Lotz ? Stefan Sauerland Keywords: Catheter Ablation, Pulmonary DiseaseChronic Obstructive, Assessment of Potential, Benefit Assessment Extract of addendum H18-02 Version 1.0 Targeted lung denervation for COPD 27 April 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - iii - Executive summary On 22 March 2018

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

20. Fluticasone furoate/umeclidinium/vilanterol (COPD) – Addendum to Commission A18-15

status”, “geographical region”, “visit”, “baseline” and the interaction terms for “baseline” and “visit” as well as for “treatment group” and “visit”. c: Institute’s calculation. CAT: COPD Assessment Test; COPD: chronic obstructive pulmonary disease; CI: confidence interval; FF: fluticasone furoate; MD: mean difference; MMRM: mixed-effects model repeated measures; N: number of analysed patients; RCT: randomized controlled trial; SD: standard deviation; SGRQ: St. George`s Respiratory Questionnaire; SE (...) -responders. c: Patients with a reduction in SGRQ total score by = 4 points (a reduction in score indicates improvement). Patients with missing values at baseline or at the date of analysis were rated as non-responders. CAT: COPD Assessment Test; CI: confidence interval; COPD: chronic obstructive pulmonary disease; FF: fluticasone furoate; n: number of patients with (at least one) event; N: number of analysed patients; RCT: randomized controlled trial; RR: relative risk; SGRQ: St. George`s Respiratory

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)